Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAY001 in Healthy Volunteers
NCT06845839Phase 1Recruiting
- Sponsor
- Cayuga Biotech
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hemorrhage comparing CAY001 with Placebo (2 arms). Primary endpoints: Serious Adverse Events at 28 days, Treatment-Related Adverse Events at 28 days and 3 more. Started Dec 2025; status: recruiting.
02
Drugs
CAY001
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT06845839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06845839.